WO2002098454A3 - Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools - Google Patents

Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools Download PDF

Info

Publication number
WO2002098454A3
WO2002098454A3 PCT/BE2002/000088 BE0200088W WO02098454A3 WO 2002098454 A3 WO2002098454 A3 WO 2002098454A3 BE 0200088 W BE0200088 W BE 0200088W WO 02098454 A3 WO02098454 A3 WO 02098454A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
intermediates
obtaining
methods
pharmaceutical compositions
Prior art date
Application number
PCT/BE2002/000088
Other languages
French (fr)
Other versions
WO2002098454A2 (en
Inventor
Marc Gaston Jacquemin
Jean-Marie Robert Saint-Remy
Original Assignee
Collen Res Foundation Vzw Onde
Marc Gaston Jacquemin
Jean-Marie Robert Saint-Remy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2001/006297 external-priority patent/WO2002096454A1/en
Priority claimed from GB0127321A external-priority patent/GB0127321D0/en
Application filed by Collen Res Foundation Vzw Onde, Marc Gaston Jacquemin, Jean-Marie Robert Saint-Remy filed Critical Collen Res Foundation Vzw Onde
Priority to AU2002312660A priority Critical patent/AU2002312660A1/en
Publication of WO2002098454A2 publication Critical patent/WO2002098454A2/en
Publication of WO2002098454A3 publication Critical patent/WO2002098454A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Abstract

The invention provides a recombinant mammalian protein modified to eliminate or reduce by at least about 80 %, with respect to activation by the wild-type protein, the activation of at least one T-cell clone derived from a mammal with antibody against the wild-type protein, the said recombinant protein having, in itsactiveform, a specific activity higher than 0.1, for use as a medicament. The recombinant protein is useful for making a pharmaceutical composition for the prevention or treatment of a disease induced by a lack or a dysfunction of a human protein, such as hemophilia.
PCT/BE2002/000088 2001-05-31 2002-05-31 Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools WO2002098454A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002312660A AU2002312660A1 (en) 2001-05-31 2002-05-31 Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPPCT/EP01/06297 2001-05-31
PCT/EP2001/006297 WO2002096454A1 (en) 2001-05-31 2001-05-31 Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
GB0127321.8 2001-11-14
GB0127321A GB0127321D0 (en) 2001-11-14 2001-11-14 Recombinant molecules with reduced immunogenicity methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostics to

Publications (2)

Publication Number Publication Date
WO2002098454A2 WO2002098454A2 (en) 2002-12-12
WO2002098454A3 true WO2002098454A3 (en) 2004-03-18

Family

ID=26069219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2002/000088 WO2002098454A2 (en) 2001-05-31 2002-05-31 Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools

Country Status (2)

Country Link
AU (1) AU2002312660A1 (en)
WO (1) WO2002098454A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2821832T3 (en) 2004-11-12 2021-04-27 Bayer Healthcare Llc Site-directed modification of FVIII
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
WO2013057219A1 (en) * 2011-10-18 2013-04-25 Csl Behring Gmbh Method for improving the stability of purified factor viii after reconstitution

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426913A1 (en) * 1989-11-07 1991-05-15 Baxter International Inc. Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
WO1999053038A2 (en) * 1998-04-15 1999-10-21 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
WO2000074688A1 (en) * 1999-06-08 2000-12-14 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
WO2001040281A2 (en) * 1999-12-02 2001-06-07 Thromb-X N.V. Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426913A1 (en) * 1989-11-07 1991-05-15 Baxter International Inc. Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
WO1999053038A2 (en) * 1998-04-15 1999-10-21 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
WO2000074688A1 (en) * 1999-06-08 2000-12-14 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
WO2001040281A2 (en) * 1999-12-02 2001-06-07 Thromb-X N.V. Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HEDNER U: "TREATMENT OF PATIENTS WITH FACTOR VIII AND FACTOR IX INHIBITORS WITH SPECIAL FOCUS ON THE USE OF RECOMBINANT FACTOR VIIA", THROMBOSIS AND HAEMOSTASIS, STUTTGART, DE, vol. 82, no. 2, August 1999 (1999-08-01), pages 531 - 539, XP001021613, ISSN: 0340-6245 *
JACQUEMIN M ET AL: "A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 95, no. 1, 1 January 2000 (2000-01-01), pages 156 - 163, XP002150704, ISSN: 0006-4971 *
JACQUEMIN M G ET AL: "MECHANISM AND KINETICS OF FACTOR VIII INACTIVATION: STUDY WITH AN IGG4 MONOCLONAL ANTIBODY DERIVED FROM A HEMOPHILIA A PATIENT WITH INHIBITOR", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 92, no. 2, 1998, pages 496 - 506, XP000906844, ISSN: 0006-4971 *
JACQUEMIN MARC ET AL: "A novel cause of mild/moderate hemophilia A: Mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.", BLOOD, vol. 96, no. 3, 1 August 2000 (2000-08-01), pages 958 - 965, XP002176173, ISSN: 0006-4971 *
PEERLINCK KATHELIJNE ET AL: "Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.", BLOOD, vol. 93, no. 7, 1 April 1999 (1999-04-01), pages 2267 - 2273, XP002176174, ISSN: 0006-4971 *
TAKAHASHI ISAO ET AL: "Change of antigenic and neutralizing specificity in substitutional epitope peptides of hemophilia B inhibitor.", PEPTIDES (NEW YORK), vol. 19, no. 7, 1998, pages 1129 - 1136, XP001037525, ISSN: 0196-9781 *
TAKAHASHI ISAO ET AL: "Epitope mapping of human factor IX inhibitor antibodies.", BRITISH JOURNAL OF HAEMATOLOGY, vol. 88, no. 1, 1994, pages 166 - 173, XP001022869, ISSN: 0007-1048 *

Also Published As

Publication number Publication date
AU2002312660A1 (en) 2002-12-16
WO2002098454A2 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
EP1806364A3 (en) New anti-IGF-IR antibodies and their applications
WO2004016750A3 (en) FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
WO2004024068A3 (en) Novel composition and methods for the treatment of immune related diseases
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001036640A3 (en) Human fgf-21 gene and gene expression products
EP2322200A3 (en) Compositions and methods for the treatment of immune related diseases
EP1347730A4 (en) Recombinant anti-cd30 antibodies and uses thereof
WO1997017446A3 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
TR200102733T2 (en) Recombinant IL-18 antagonists useful in the treatment of IL-18 related disorders
EP2348034A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2002083849A3 (en) Vascular endothelial growth factor 2
WO2004024097A8 (en) Compositions and methods for the treatment of immune related diseases
WO2000073452A3 (en) Compositions and methods for the treatment of immune related diseases
DE69840909D1 (en) ANALOG OF COCAINE
EP1969003B8 (en) Uses of a NEUROTROPHIC FACTOR PROTEIN
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
WO2004055201A3 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
WO2002098454A3 (en) Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002081507A3 (en) Interferon gamma polypeptide variants
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP